Feb. 12 /PRNewswire/ -- HTS Biosystems announced today that it has signed a nonexclusive license exchange agreement with Dyax Corp. (Nasdaq: DYAX - news) that will provide both companies with tools to accelerate the discovery and validation of novel therapeutic targets.
Under the terms of the agreement, Dyax will receive premarket access to HTS's grating-coupled surface plasmon resonance (SPR) array system that is designed to accelerate the validation of novel drug targets discovered with Dyax's phage display technology. In exchange, Dyax will grant HTS a patent license to use its proprietary phage display technology for the generation of antibody chip products for the HTS system, for which Dyax would receive royalties on sales.
HTS's surface plasmon resonance technology is an enabling and infinitely flexible proteomics tool that combines the strengths of biology and physics to maximize protein chip productivity. Greg Freitag, CEO of HTS Biosystems commented, ``Through the success of its internal programs, licensing arrangements and collaborations, Dyax has demonstrated the effectiveness of its phage display technology. The addition of Dyax's discovery platform to our proteomics technology portfolio expands the tools that HTS can provide to its customers to allow them to streamline their drug discovery and development programs.''
``Employing our phage display technology, Dyax can rapidly and efficiently identify therapeutic candidates contained within our diverse protein, peptide and antibody libraries,'' said Henry Blair, president and CEO of Dyax Corp. ``The HTS system has the potential to greatly increase the throughput of our therapeutic candidate validation, resulting in a more rapid discovery of products for our pipeline and those of our collaborators.''
HTS Biosystems, Inc. (http://www.htsbiosystems.com) applies a unique portfolio approach to provide high-throughput bioanalytical systems for the rapidly growing field of proteomics. This portfolio includes novel label-free detection systems as well as advanced fluorescence-based technologies to provide a comprehensive suite of tools supporting all phases of drug discovery and development of unique diagnostics. HTS Biosystems was formed by combining technology and intellectual property from its initial shareholders, including its major shareholders, Quantech Ltd. (http://www.quantechltd.com; OTC Bulletin Board: QQQQ - news) and Applied Biosystems, Inc. This technology portfolio has been expanded, and collaborations with Protein Sciences Corporation, Boston Probes, Ciencia, Inc., and Mitsubishi Chemical Corporation have been formed, positioning HTS Biosystems to become the definitive source of various high-throughput systems and chemistries for the detection of molecular interactions and cellular changes... |
